Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results

European Journal of Ophthalmology

Volumn 26, Issue 5, 2016, Pages 473-478

  Aghdam, Kaveh Abri ^a,b   Pielen, Amelie ^a   Framme, Carsten ^a   Junker, Bernd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aflibercept; Age related macular degeneration; Choroidal neovascularization; Spectral domain optical coherence tomography

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; B SCAN; CENTRAL SUBFIELD THICKNESS; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MACULAR VOLUME; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; DRUG SUBSTITUTION; EYE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; DIABETIC RETINOPATHY; DRUG SUBSTITUTION; EYE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84984914543     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000757     Document Type: Article

References (30)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640-1642.
2. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovas-cular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37(9):1929-1934.
3. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82(1):99-110.
4. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154-162.
5. Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1246-1251.
6. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. Am J Ophthalmol. 2012;153(6): 1116-24.
7. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
8. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185.
9. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12): 2537-2548.
10. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1): 15-22.
11. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23-28.
12. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35.
13. Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51(3): 1671-1676.
14. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1-2.
15. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-23.
16. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neo-vascularisation. Br J Ophthalmol. 2012;96(1):14-20.
17. Tranos P, Vacalis A, Asteriadis S, et al. Resistance to antivascu-lar endothelial growth factor treatment in age-related macular degeneration. Drug Des Dev Ther. 2013;7:485-490.
18. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA. 2009;106(15):6152-6157.
19. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(7):3186-3193.
20. Lazzeri S, Ripandelli G, Sartini MS, et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18(4):397-432.
21. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol. 2007;52(Suppl 1):S3-S19.
22. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmo-logica. 2012;227(Suppl 1):2-10.
23. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
24. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye. 2014;28(7):895-899.
25. Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426-36.
26. Messenger WB, Campbell JP, Faridi A, et al. Injection frequency and anatomic outcomes 1 year following conversion to afliber- cept in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1205-1207.
27. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-192.
28. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605-1612.
29. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology. 2009;116(9):1740-1747.
30. Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol. 2014;98(Suppl 1): i22-i27.